- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07493577
Soppressione Indotta dell'Attività Piastrinica nella Gestione dell'Emorragia Subaracnoidea Aneurismatica-2 (iSPASM-2) (iSPASM-2)
Soppressione Indotta dell'Attività Piastrinica nella Gestione dell'Emorragia Subaracnoidea Aneurismatica-2
An exploratory, randomized, double-blinded, placebo-controlled, two-center clinical trial to determine the maximum tolerated dosage of intravenous tirofiban in patients with aneurysmal subarachnoid hemorrhage (aSAH) post-endovascular coiling. The study will also assess pharmacology and safety, with exploratory endpoints including delayed cerebral ischemia (DCI), vasospasm, and functional outcomes.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an exploratory, two-center, randomized, double-blinded study. The primary objective is to determine the maximum tolerated dosage (MTD) of tirofiban in the context of patients with aSAH status post-endovascular coiling. The dosage regimen of tirofiban will be 0.10µg/kg/min (actual weight) within 48 hours of aneurysm securing and within 72 hours of ictus.
The study will involve a dose escalation stage and a cohort expansion stage. During the dosage-escalation stage, the intervention doses include continuous intravenous (IV) tirofiban or IV placebo for 1 day, 3 days, 5 days, or 7 days. Dose-escalation will follow the time-to-event Bayesian Optimal Intervention (TITE-BOIN) design. Unlike the majority of existing phase I designs, which require suspending the accrual after treating each cohort of patients, the TITE-BOIN design allows for real-time dose assignment decisions for new patients while the toxicity data are still pending for some patients under treatment. This shortens the trial duration and reduces the logistical difficulties caused by frequent suspensions of accrual. For parallel comparison under real-world conditions, patients will be randomly assigned to tirofiban and placebo in a 2:1 ratio in the dose escalation stage. The data from the placebo patients will not be analyzed to inform dose escalation but included in the final analysis upon study completion. Upon the completion of the dose escalation stage, the MTD will be selected using isotonic regression. MTD will be selected as the dosage for which the isotonic estimate of the toxicity rate is closest to the target dosage-limiting toxicity rate (30%). If there is a tie, we will select the higher dosage level when the isotonic estimate is lower than the target toxicity rate, and we will select the lower dosage level when the isotonic estimate is greater than or equal to the target toxicity rate.
During the cohort expansion stage, patients will be randomized to tirofiban at MTD and placebo at the corresponding dosage level to achieve balanced sample sizes (30 tirofiban at MTD and 30 placebo for any infusion duration, combined from both phases) across the two groups. The analysis of the exploratory endpoints will be performed on the tirofiban patients at MTD and placebo patients with any infusion duration.
An interim pharmacokinetic (PK) analysis will be performed after 10 evaluable patients are treated with tirofiban to determine possible dose modification. At the completion of the study, PK and pharmacodynamic (PD) analysis will be conducted using all evaluable patients treated with tirofiban to determine whether augmented renal clearance in aSAH interacts with the pharmacokinetics and pharmacodynamics of tirofiban.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Beth Perry
- Numero di telefono: 919-681-2695
- Email: beth.perry@duke.edu
Backup dei contatti dello studio
- Nome: Hazani Benitez-Rosas
- Numero di telefono: 919-681-4974
- Email: hazani.benitez-rosas@duke.edu
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Health System
-
Contatto:
- Hazani Benitez-Rosas, AS
- Numero di telefono: 919-681-4974
- Email: hazani.benitez-rosas@duke.edu
-
Contatto:
- Beth A Perry, RN
- Numero di telefono: 919-681-2695
- Email: beth.perry@duke.edu
-
Investigatore principale:
- Emad Hasan, MD
-
Investigatore principale:
- Brian Mac Grory, MD
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- University of Texas Health Sciences Center
-
Contatto:
- Sprios Blackburn, MD
- Numero di telefono: 713-486-8000
- Email: Spiros.Blackburn@uth.tmc.edu
-
Investigatore principale:
- Spiros Blackburn, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion:
- Age 18-85
- Baseline Modified Rankin Scale (mRS) 0-3 (pre-SAH)
- SAH attributed to ruptured cerebral aneurysm
- Admission Computed Tomography (CT) scan shows Modified Fisher grade 1-4 due to aSAH primarily in the supratentorial space
- World Federation of Neurosurgical Societies (WFNS) scale grade ≤4 at randomization
- Onset of symptoms of aSAH (ictus) occurred <72 hours prior to presentation
- If External Ventricular Drain (EVD) placed, placement is ≥12 hours prior to enrollment
- All aneurysm(s) suspected to be responsible for the hemorrhage must be secured via Endovascular Coil Embolization with a post-embolization Raymond-Roy Score of 1 (Complete) or 2 (Residual Neck) prior to enrollment
- Participant can be randomized within 48 hours of aneurysm treatment
- Participant or participant's legally-authorized representative (LAR) has provided documented informed consent
Exclusion:
-
Angio-negative SAH, defined as a SAH with a digital subtraction angiogram that does not show an intracranial aneurysm
-
Surgical clipping prior of the ruptured aneurysm or any non-ruptured aneurysm on the same admission to enrollment
-
Remaining untreated aneurysm(s) that could reasonably be considered a possible alternate cause of the aSAH based on the observed bleeding pattern
-
Uncontrollable hypertension (>180 systolic and/or >110 diastolic) that is not correctable prior to enrollment
-
Active internal bleeding, or history of bleeding diathesis, major surgical procedure, or severe physical trauma within the previous month (30 days)
-
A medical diagnosis that requires continuous use of aspirin, clopidogrel, ticagrelor, or tirofiban during the study drug infusion
-
New parenchymal hemorrhage or new infarction larger than 15 cubic centimeters (cc) in volume by CT
-
Thrombolytic therapy within 24 hours prior to enrollment (alteplase, tenecteplase, or urokinase)
-
Previous intracranial hemorrhage, intracranial neoplasm, subarachnoid hemorrhage, or arterial-venous malformation
-
Thrombocytopenia (platelet count <100,000/microliter (µL) assuming clumping is ruled out
-
Allergy or intolerance to tirofiban
-
Pregnant or lactating
-
Chronic kidney disease with creatinine clearance (CrCl ≤ 30 milliliters per minute [ml/min]) or acute kidney injury (AKI) at study screening. AKI is defined as:
i) Increase in serum creatinine by 0.3 milligrams per deciliter (mg/dL) or more (26.5 micromoles per liter [μmol/L] or more) within 48 hour period; OR ii) Increase in serum creatinine to 1.5 times or more than the baseline of the prior 7 day period; OR iii) Urine volume less than 0.5 ml/kg/hour for at least 6 hours
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Tirofiban
Continuous IV infusion of tirofiban for 1, 3, 5, or 7 days post-endovascular coiling. |
IV infusion at 0.10 microgram/kilogram/minute (mcg/kg/min) for 1 day, 3 days, 5 days, or 7 days according to the dose escalation procedure.
Altri nomi:
|
|
Comparatore placebo: Placebo
Continuous IV infusion of saline placebo for 1, 3, 5, or 7 days post-endovascular coiling. |
IV infusion at the same infusion duration as the study drug; same adjustments
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Tirofiban dosage-limiting toxicity (DLT)
Lasso di tempo: Within 14 days post-randomization
|
Presence of any of the following: any intracranial hemorrhage, major extracranial hemorrhage (defined as clinically overt bleeding leading to death; OR clinically overt bleeding causing a reduction in hemoglobin of ≥2g/dl; OR clinically overt bleeding necessitating transfusion of ≥2 units of packed red cells or whole blood; OR clinically overt bleeding in a critical area or organ other than the intracranial compartment (including intraspinal, intraocular, pericardial, intra-articular, retroperitoneal, intramuscular [with compartment syndrome])), thrombocytopenia, or serious adverse event (SAE) due to tirofiban. |
Within 14 days post-randomization
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parametri farmacocinetici - clearance totale (Cltot)
Lasso di tempo: Fino a 7 ore dopo l'interruzione del farmaco
|
Fino a 7 ore dopo l'interruzione del farmaco
|
|
|
Parametri farmacocinetici - Volume di distribuzione (Vd)
Lasso di tempo: Fino a 7 ore dopo l'interruzione del farmaco
|
Fino a 7 ore dopo l'interruzione del farmaco
|
|
|
Pharmacokinetic parameters - Maximum (peak) plasma concentration (Cmax)
Lasso di tempo: Up to 7 hours after drug discontinuation
|
Highest concentration of tirofiban in the blood after a dose is administered |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Minimum (trough) plasma concentration (Cmin)
Lasso di tempo: Up to 7 hours after drug discontinuation
|
Lowest observed concentration of tirofiban in the blood after a dose is administered |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Average Plasma Concentration (Cavg)
Lasso di tempo: Up to 7 hours after drug discontinuation
|
Average tirofiban concentration in the blood at steady state |
Up to 7 hours after drug discontinuation
|
|
Pharmacokinetic parameters - Area Under the Concentration (AUC)Time Curve
Lasso di tempo: Up to 7 hours after drug discontinuation
|
Area under the curve from time 0 extrapolated to infinite time |
Up to 7 hours after drug discontinuation
|
|
Pharmacodynamic parameters - adenosine diphosphate (ADP)
Lasso di tempo: Baseline, 2, 6, and every 24 hours and at drug cessation
|
The percent inhibition of ADP-induced platelet aggregation |
Baseline, 2, 6, and every 24 hours and at drug cessation
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Delayed cerebral ischemia (DCI) or death without DCI
Lasso di tempo: Within 14 days post-randomization
|
This is the primary exploratory efficacy outcome, which is a composite binary outcome. DCI is defined as any of the following: a. Focal neurological impairment, b. decrease of at least 2 points on the Glasgow coma scale and/or c. cerebral infarction present on final CT or MRI, which was not present on a CT or MRI between 24-48 hours post-endovascular therapy and not attributable to other causes. |
Within 14 days post-randomization
|
|
Cerebral vasospasm
Lasso di tempo: Within 14 days post-randomization or until discharge from the index admission, which occurred later
|
Cerebral vasospasm requires confirmation of vasospasm on either CTA or DSA confirming mild vasospasm (decrease in vessel diameter by ≤25% of normal artery diameter), moderate vasospasm (decrease in vessel diameter by >25 to ≤50% of normal diameter but cerebral vasospasm), or severe vasospasm (decrease in vessel diameter by >50% of normal vessel diameter) |
Within 14 days post-randomization or until discharge from the index admission, which occurred later
|
|
Mortality
Lasso di tempo: 3 and 6 months post-randomization
|
Death of any cause |
3 and 6 months post-randomization
|
|
Total number of days in the ICU for the index admission
Lasso di tempo: Up to 6 months post-randomization
|
Total number of days from ICU admission to ICU discharge during the index hospitalization |
Up to 6 months post-randomization
|
|
Total hospital stay length for the index admission
Lasso di tempo: Up to 6 months post-randomization
|
Total number of days from admission to discharge during the index admission |
Up to 6 months post-randomization
|
|
Modified Rankin Scale (mRS)
Lasso di tempo: 3 and 6 months post-randomization
|
It is a clinician-reported measure of global disability, widely applied for evaluating stroke patient outcomes and as an endpoint in randomized clinical trials. It is a single-item 7-point scale with a range of 0 (no symptoms at all) to 6 (death), with higher scores indicating greater disability. The elements of the mRS are as follows: (1) no symptoms at all; (2) no significant disability, but there may be slight symptoms such as weakness or numbness; (3) slight disability, but able to carry out daily activities independently; (4) moderate disability, requiring some help with daily activities; (5) moderately severe disability, requiring assistance with most daily activities; (6) severe disability, bedridden and requiring constant nursing care; and (7) death. |
3 and 6 months post-randomization
|
|
Return to work
Lasso di tempo: 3 and 6 months post-randomization
|
Returned to prior level of responsibilities at work |
3 and 6 months post-randomization
|
|
Lawton Instrumental Activities of Daily Living (Lawton IADL)
Lasso di tempo: 3 and 6 months post-randomization
|
It is an instrument to assess independent living skills among older adults, and can be used in community or hospital settings. There are 8 domains of function measured with the scale: (1) using the telephone; (2) shopping; (3) preparing food; (4) housekeeping; (5) doing laundry; (6) using transportation; (7) handling medications; (8) handling finances. Women are scored on all 8 areas of function; historically, for men, the areas of food preparation, housekeeping, and laundering are excluded. Individuals are scored according to their highest level of functioning in that category. A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women, and 0 through 5 for men. |
3 and 6 months post-randomization
|
|
Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)
Lasso di tempo: 3 and 6 months post-randomization
|
It is a 6-item scale to evaluate the overall satisfaction with facets of life relevant to people with traumatic brain injury. The area covered by the questionnaire includes physical condition, cognition, emotions, function in daily life, personal and social life, and current situation and future prospects. Responses to each item were scored 1 ('Not at all') to 5 ('Very'), and the sum of all items was converted arithmetically to a percentage scale, with 0 representing the lowest possible (health-related quality of life (HRQoL) on the questionnaire and 100 the best possible HRQoL. |
3 and 6 months post-randomization
|
|
Glasgow Outcome Scale-Extended (GOS-E)
Lasso di tempo: 3 and 6 months post-randomization
|
It is used to assess global outcomes in persons with brain injury, by categorizing global function using an 8-point ordinal scale that focuses on disability and functioning in daily life. The scales are: 1. Dead, 2. Vegetative State, 3. Lower Severe Disability (SD), 4. Upper SD, 5. Lower Moderate Disability (MD), 6. Upper MD, 7. Lower Good Recovery (GR), 8. Upper GR |
3 and 6 months post-randomization
|
|
PROMIS-29+2
Lasso di tempo: 3 and 6 months post-randomization
|
The Patient-Reported Outcomes Measurement Information System® (PROMIS) is a flexible set of tools designed to measure self-reported physical, mental, and social health and wellbeing. PROMIS-29+2 is a collection of 4-item Likert-item short forms assessing the following domains:
Norm-based scores will be calculated for each domain on the PROMIS measures, so that a score of 50 represents the mean or average of the reference population. A score of 60 means that the person is one standard deviation above the reference population (standard deviation = 10). For PROMIS measures, higher scores equal more of the concept being measured (e.g., more Fatigue, more Physical Function). |
3 and 6 months post-randomization
|
|
Montreal Cognitive Assessment (MoCA)
Lasso di tempo: 3 and 6 months post-randomization
|
It is a 30-point test to assess people for dementia. The MoCA evaluates different types of cognitive abilities, including orientation, short-term memory / delayed recall, executive function / visuospatial ability, language ability, abstraction, animal naming, attention, and clock-drawing. Scores range from 0 to 30, with a score of 26 or higher considered normal. |
3 and 6 months post-randomization
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Emad Hasan, MD, Duke University
- Investigatore principale: Brian Mac Grory, MD, Duke University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie vascolari
- Malattia cardiovascolare
- Processi patologici
- Emorragia
- Emorragie intracraniche
- Condizioni patologiche, segni e sintomi
- Emorragia subaracnoidea
- Aminoacidi, peptidi e proteine
- Preparati farmaceutici
- Aminoacidi
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Aminoacidi, aromatici
- Aminoacidi, ciclici
- Tirosina
- Tirofibano
- Soluzione salina
Altri numeri di identificazione dello studio
- Pro00119469
- UG3NS138219 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .